GLP-1 Receptor Agonists Explained

A GLP-1 receptor agonist is a drug that imitates a hormone your gut releases after you eat. Every major weight loss medicine of the last decade is one, or is built around one.

The reason a single hormone came to dominate an entire field is worth understanding, because it explains both why these drugs work and what they cannot do. GLP-1 is one of the signals that tells the brain a meal has arrived and enough has been eaten. Drugs that copy it do not burn fat, raise metabolism or block absorption. They change how hungry a person is.

That is a narrower mechanism than the marketing around it suggests, and it is also why stopping the drug returns appetite to where it started.

What GLP-1 is#

Glucagon-like peptide-1 is a hormone released by cells in the wall of the small intestine when food passes through. It is what endocrinologists call an incretin: a gut signal that tells the pancreas a meal is on its way.

It does three things worth knowing about.

• It prompts insulin release, but only when glucose is present. This is why drugs in this class lower blood sugar without the hypoglycaemia risk older diabetes medicines carry. No meal, no insulin push.
• It suppresses glucagon. Glucagon is the hormone that tells the liver to release stored sugar between meals. Dampening it lowers fasting blood sugar.
• It acts on appetite centres in the brain. Directly, in the hypothalamus and brainstem, which is the effect people notice.

Natural GLP-1 is destroyed within about two minutes by an enzyme called DPP-4. That short life is the entire engineering problem these drugs solve.

Why the hormone had to be modified#

A drug that lasted two minutes would be useless. Every GLP-1 receptor agonist is the natural hormone with changes made to stop the body clearing it.

Semaglutide is the clearest example. One amino acid is swapped at the site DPP-4 attacks, another is substituted, and a fatty acid chain is attached that binds the molecule to albumin in the blood so the kidneys do not filter it out. Two minutes becomes about a week.

Those three edits are the difference between a hormone and a medicine. The receptor activity is essentially the same.

What these drugs are claimed to do#

Reduce appetite#

The claim is that a person stops wanting to eat as much, rather than resisting the urge to.

GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger signalling, and slowed gastric emptying means food stays in the stomach longer.

In practice that describes a meal ending at a point that would previously have felt like halfway, and the next one not arriving in your thoughts until it is due. Users consistently describe it as background noise going quiet rather than as willpower.

This has been measured as body weight in large randomised placebo-controlled trials across the class, with results ranging from roughly 5% for the oldest drugs to 28% for the newest experimental ones.

Lower blood sugar#

The claim is reliable reduction in HbA1c in type 2 diabetes, which is where this class started and where its record is longest.

Glucose-dependent insulin secretion plus glucagon suppression lowers both post-meal spikes and fasting levels.

Put another way, the pancreas responds when food arrives and the liver stops volunteering sugar when it has not.

This has been measured since the first agents were licensed in the mid-2000s, and is the least contested claim in the field.

Reduce cardiovascular events#

The claim is the strongest one available: that taking the drug changes whether something happens to a person rather than changing a measurement.

The mechanism is not settled. Weight loss, blood pressure, lipids and a direct anti-inflammatory effect on vessel walls have all been proposed, and the effect appeared larger than weight loss alone would predict.

What that looks like to a person is an event that does not occur.

This has been measured for semaglutide in SELECT and for liraglutide in LEADER. It has not been measured for tirzepatide or retatrutide, whose trials are running rather than finished. This is a claim that belongs to specific drugs, not to the class.

How the drugs in this class differ#

The useful way to sort them is by how many receptors they hit.

• Single agonists. GLP-1 only. Liraglutide, daily, roughly 5 to 8% weight loss. Semaglutide, weekly, roughly 15%.
• Dual agonists. GLP-1 and GIP. Tirzepatide, weekly, roughly 20%. GIP is the other main incretin, and its contribution was considered unhelpful for years before these results forced a reassessment.
• Triple agonists. GLP-1, GIP and glucagon. Retatrutide, weekly, up to 28.3% in phase 3 and not approved anywhere. The glucagon arm raises energy expenditure, so it acts on what is burned as well as what is eaten.
• A different mechanism entirely. Cagrilintide works through amylin rather than the incretin receptors, and is being developed alongside semaglutide rather than as a replacement for it.

The pattern is that more receptors has so far meant more weight loss. That is a description of the results to date rather than a law, and each addition brings its own side effect profile.

What the evidence actually supports#

• Species and route. Human, at the route people use, in randomised placebo-controlled trials involving tens of thousands of participants. This class is the exception to almost everything else covered on this site.
• Concentration of sources. The pivotal trials are sponsored by two companies, Novo Nordisk and Eli Lilly. For the older agents this is now supplemented by a decade of independent prescribing data; for the newest it is not.
• Human data. Extensive for weight and blood sugar. Cardiovascular outcomes exist for two drugs and not for the rest.
• What has not been looked at. Use over decades. Long-term effects on lean mass. And the averages hide a wide spread, with no reliable way to predict who responds strongly.

The summary: the class works, the effect sizes are real and large, and the specific claim being made matters more than the class label. "GLP-1 drugs reduce heart attacks" is true of semaglutide and unproven for most of the others.

Side effects across the class#

The common problems are digestive and shared: nausea, diarrhoea, constipation, vomiting and reflux, worst early and after each dose increase, mostly settling. Every drug in this class uses a slow dose escalation for that reason.

The labels for semaglutide and tirzepatide both advise against use with a personal or family history of medullary thyroid carcinoma or MEN2, on the basis of rodent tumours that have not been demonstrated in humans.

Loss of lean tissue alongside fat applies to the whole class and scales with how much weight is lost, which means it matters most with the newest and strongest agents.

Frequently asked questions#

Do these drugs speed up metabolism?

No. They reduce how much a person eats, principally by acting on appetite. The triple agonists add a glucagon arm that does raise energy expenditure, which makes retatrutide the partial exception rather than the rule.

Why does the weight come back?

Because the drugs treat appetite while they are present rather than resetting anything. When the drug clears, appetite regulation returns to where it was. Every withdrawal trial in the class has shown substantial regain.

Is a compounded or research-labelled version the same drug?

It shares a name. Nothing on the label of a vial establishes what is in it or at what concentration, and the trial results describe a molecule of verified identity. How to read a peptide study without being fooled covers the gap between what a trial shows and what a product claim implies.

Which one is best?

For weight alone, more receptors has so far meant more loss. For proven cardiovascular benefit, semaglutide is the one with the completed trial. Those are different questions with different answers.

Key takeaways#

• A GLP-1 receptor agonist copies a gut hormone that signals fullness after a meal. The drugs are the natural hormone modified so the body cannot clear it within minutes.
• They reduce appetite. They do not burn fat, raise metabolism or block absorption, which is why appetite returns when they are stopped.
• Adding receptors has so far increased weight loss: GLP-1 alone gives roughly 5 to 15%, adding GIP gives about 20%, adding glucagon gave up to 28.3% in phase 3.
• Cardiovascular benefit is proven for semaglutide and liraglutide specifically. It is not established for tirzepatide or retatrutide, whose trials have not reported.
• Digestive side effects are shared across the class, and sustained severe abdominal pain is a same-day medical question rather than something to wait out.

References#

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023.
3. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016. The LEADER trial.
4. The compound pages on this site: semaglutide, tirzepatide, retatrutide, liraglutide.